Isacco Ferrarini

19PUBLICATIONS
105CO-AUTHORS
AutoimmunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|May 01, 2026
Serositis as possible manifestation in MDS/AML patients with complex karyotype and TP53 mutation: case series.

|Jan 07, 2026
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Enrica Antonia Martino, Annalisa Pitino, Ernesto Vigna

|Nov 10, 2025
Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies.

Edoardo Tamellini, Cristina Frusteri, Isacco Ferrarini

|Apr 16, 2025
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.

Andrea Serafin, Alessandro Cellini, Enrica Antonia Martino

|Nov 14, 2024
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia.

Marilisa Galasso, Vittoria Salaorni, Riccardo Moia

|Oct 16, 2024
The Importance of Real-World Data in Evaluating the Safety of Biosimilars: A Descriptive Study of Clinical Practice in an Oncohematological Italian Population.

Silvana A M Urru, Flavia Mayer, Stefania Spila Alegiani

Pageof 4

Frequent Collaborators

7 joint publications

Luca Laurenti

6 joint publications

Anna Maria Frustaci

6 joint publications

Carlo Visco

5 joint publications

Raffaella Pasquale